UK scientists to immunize hundreds with coronavirus vaccine

Remigio Civitarese
Agosto 1, 2020

Tests have shown that the vaccine promotes the creation of protective antibodies.

J&J's vaccine uses a common cold virus known as adenovirus type 26 or Ad26 to ferry coronavirus proteins into cells in the body, causing the body to mount an immune defense against the virus.

NY:A leading candidate of Covid-19 vaccine developed by global healthcare company Johnson & Johnson raised neutralising antibodies and robustly protected monkeys against SARS-CoV-2, the virus that causes Covid-19.

It says the vaccine prevented infection by providing complete or near-complete protection in the lungs from the virus in non-human primates in the pre-clinical study.

"On Wednesday, we received the first consignment of 34 Covaxin developed by Bharat Biotech International and on Friday, we received 20 Covaxin developed by drug firm Zydus Cadila and we are expecting more vaccines from the companies soon", Mr Chaturvedi said. But in a pandemic a single-shot vaccine has a significant advantage, sidestepping a lot of the logistical issues involved in getting people to come back for their second dose. Six weeks after the immunization, all animals were exposed to SARS-CoV-2. All 20 animals that received the placebos became infected and showed high levels of virus in their lungs and nasal swabs.

Investigators at BIDMC and other institutions have initiated a first-in-human phase 1/2 clinical trial of the vaccine in healthy volunteers.

"We look forward to the results of the clinical trials that will determine the safety and immunogenicity, and ultimately the efficacy, of the Ad26.COV2.S vaccine in humans", the authors wrote.

"We now need to move into larger scale real-world trials, but it is good to see more data and more products moving into this very important phase of vaccine discovery".

The minister, who did not give details about the vaccine to be used, said doctors and teachers would be the first to be vaccinated.

Altre relazioniGrafFiotech

Discuti questo articolo

Segui i nostri GIORNALE